Biological Agents in Kidney Transplantation

Chronic Kidney Disease, Dialysis, and Transplantation

Volumn , Issue , 2010, Pages 509-515

  Huang, Edmund ^a   Womer, Karl L ^a   Vincenti, Flavio ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882470227     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-0987-2.00035-2     Document Type: Chapter

References (88)

1. Starzl T.E., Marchioro T.L., Hutchinson D.E., Porter K.A., Cerilli G.J., Brettschneider L. The clinical use of antilymphocyte globulin in renal homotransplantation. Transplantation 1967, 5(Suppl. 4):1100-1105.
2. Gaber A.O., First M.R., Tesi R.J., et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998, 66(1):29-37.
3. Howard R.J., Condie R.M., Sutherland D.E., Simmons R.L., Najarian J.S. The use of antilymphoblast globulin in the treatment of renal allograft rejection: a double-blind, randomized study. Transplantation 1977, 24(6):419-423.
4. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006 2007, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD.
5. Kahan B.D., Rajagopalan P.R., Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999, 67(2):276-284.
6. Nashan B., Light S., Hardie I.R., Lin A., Johnson J.R. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999, 67(1):110-115.
7. Nashan B., Moore R., Amlot P., Schmidt A.G., Abeywickrama K., Soulillou J.P. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997, 350(9086):1193-1198.
8. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 1998, 338(3):161-165.
9. Szczech L.A., Berlin J.A., Aradhye S., Grossman R.A., Feldman H.I. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J. Am. Soc. Nephrol. 1997, 8(11):1771-1777.
10. Szczech L.A., Berlin J.A., Feldman H.I. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann. Intern. Med. 1998, 128(10):817-826.
11. Barth R.N., Janus C.A., Lillesand C.A., Radke N.A., Pirsch J.D., Becker B.N., et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl. Int. 2006, 19(11):885-892.
12. Flechner S.M., Friend P.J., Brockmann J., et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am. J. Transplant. 2005, 5(12):3009-3014.
13. Flechner S.M., Goldfarb D., Solez K., et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007, 83(7):883-892.
14. Kandaswamy R., Melancon J.K., Dunn T., et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients-an interim analysis. Am. J. Transplant. 2005, 5(6):1529-1536.
15. Kaufman D.B., Leventhal J.R., Axelrod D., Gallon L.G., Parker M.A., Stuart F.P. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am. J. Transplant. 2005, 5(10):2539-2548.
16. Bunnapradist S., Takemoto S.K. Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants. Transplant. Proc. 2005, 37(2):889-891.
17. Goggins W.C., Pascual M.A., Powelson J.A., et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003, 76(5):798-802.
18. Schadde E., D'Alessandro A.M., Knechtle S.J., et al. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transpl. Int. 2008, 21(7):625-636.
19. Bestard O., Cruzado J.M., Mestre M., et al. Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T-cell recruitment in human renal allograft infiltrates. J. Immunol. 2007, 179(7):4901-4909.
20. Brennan D.C., Flavin K., Lowell J.A., et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999, 67(7):1011-1018.
21. Hardinger K.L., Rhee S., Buchanan P., et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008, 86(7):947-952.
22. Hardinger K.L., Schnitzler M.A., Miller B., et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004, 78(1):136-141.
23. Brennan D.C., Daller J.A., Lake K.D., Cibrik D., Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 2006, 355(19):1967-1977.
24. Brennan D.C., Schnitzler M.A. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N. Engl. J. Med. 2008, 359(16):1736-1738.
25. Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 1995, 105(1):23-29.
26. Kimball J.A., Norman D.J., Shield C.F., et al. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transpl. Immunol. 1995, 3(3):212-221.
27. Kirk A.D., Mannon R.B., Kleiner D.E., et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005, 80(8):1051-1059.
28. Calne R., Friend P., Moffatt S., et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998, 351(9117):1701-1702.
29. Watson C.J., Bradley J.A., Friend P.J., et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am. J. Transplant. 2005, 5(6):1347-1353.
30. Knechtle S.J., Pirsch J.D., Fechner J.H, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. 2003, 3(6):722-730.
31. Vo A.A., Toyoda M., Peng A., Bunnapradist S., Lukovsky M., Jordan S.C. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am. J. Transplant. 2006, 6(10):2384-2390.
32. Vo A.A., Wechsler E.A., Wang J., et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am. J. Transplant. 2008, 8(1):144-149.
33. Vo A.A., Lukovsky M., Toyoda M., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 2008, 359(3):242-251.
34. Coles A.J., Wing M., Smith S., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999, 354(9191):1691-1695.
35. Jones J.L., Phuah C.L., Cox A.L., et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 2009, 119(7):2052-2061.
36. Kirk A.D., Hale D.A., Swanson S.J., Mannon R.B. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am. J. Transplant. 2006, 6(5 Pt 1):1084-1085.
37. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin. Transplant. 2008, 22(2):200-210.
38. Farney A., Sundberg A., Moore P., et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin. Transplant. 2008, 22(1):41-49.
39. Vathsala A., Ona E.T., Tan S.Y., et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005, 80(6):765-774.
40. Waldmann T.A., Goldman C.K. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts. Am. J. Kidney Dis. 1989, 14(5 Suppl. 2):45-53.
41. Kirkman R.L., Shapiro M.E., Carpenter C.B., et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991, 51(1):107-113.
42. Soulillou J.P., Cantarovich D., Le Mauff B., et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N. Engl. J. Med. 1990, 322(17):1175-1182.
43. Amlot P.L., Rawlings E., Fernando O.N., et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995, 60(7):748-756.
44. Kovarik J.M., Kahan B.D., Rajagopalan P.R., et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation 1999, 68(9):1288-1294.
45. Vincenti F., Ramos E., Brattstrom C., et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001, 71(9):1282-1287.
46. Tobinai K., Kobayashi Y., Narabayashi M., et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann. Oncol. 1998, 9(5):527-534.
47. Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006, 54(9):2793-2806.
48. Gloor J.M., DeGoey S.R., Pineda A.A., et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am. J. Transplant. 2003, 3(8):1017-1023.
49. Sawada T., Fuchinoue S., Kawase T., Kubota K., Teraoka S. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin. Transplant. 2004, 18(3):254-260.
50. Vincenti F., Pace D., Birnbaum J., Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am. J. Transplant. 2003, 3(1):50-52.
51. Segev D.L., Simpkins C.E., Warren D.S., et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am. J. Transplant. 2005, 5(10):2570-2575.
52. Sonnenday C.J., Warren D.S., Cooper M., et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am. J. Transplant. 2004, 4(8):1315-1322.
53. Stegall M.D., Gloor J., Winters J.L., Moore S.B., Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant. 2006, 6(2):346-351.
54. Faguer S., Kamar N., Guilbeaud-Frugier C., et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007, 83(9):1277-1280.
55. Chong E.A., Svoboda J., Cherian S., et al. Regression of pulmonary MALT lymphoma after treatment with rituximab. Leuk. Lymphoma 2005, 46(9):1383-1386.
56. Davis T.A., White C.A., Grillo-Lopez A.J., et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J. Clin. Oncol. 1999, 17(6):1851-1857.
57. Choquet S., Leblond V., Herbrecht R., et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006, 107(8):3053-3057.
58. Elstrom R.L., Andreadis C., Aqui N.A., et al. Treatment of PTLD with rituximab or chemotherapy. Am. J. Transplant. 2006, 6(3):569-576.
59. Oertel S.H., Verschuuren E., Reinke P., et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am. J. Transplant. 2005, 5(12):2901-2906.
60. Ruggenenti P., Chiurchiu C., Brusegan V., et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J. Am. Soc. Nephrol. 2003, 14(7):1851-1857.
61. Sfikakis P.P., Boletis J.N., Lionaki S., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T-cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005, 52(2):501-513.
62. Zaja F., De Vita S., Mazzaro C., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101(10):3827-3834.
63. Benz K., Dotsch J., Rascher W., Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr. Nephrol. 2004, 19(7):794-797.
64. Fervenza F.C., Cosio F.G., Erickson S.B., et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008, 73(1):117-125.
65. Gallon L., Chhabra D. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am. J. Transplant. 2006, 6(12):3017-3021.
66. Weclawiak H., Ribes D., Guilbeau-Frugier C., et al. Relapse of membranous glomerulopathy after kidney transplantation: sustained remittance induced by rituximab. Clin. Nephrol. 2008, 69(5):373-376.
67. Vincenti F., Ghiggeri G.M. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am. J. Transplant. 2005, 5(6):1179-1185.
68. Reiser J., von Gersdorff G., Loos M., et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J. Clin. Invest. 2004, 113(10):1390-1397.
69. Gossmann J., Scheuermann E.H., Porubsky S., Kachel H.G., Geiger H., Hauser I.A. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl. Int. 2007, 20(6):558-562.
70. Yabu J.M., Ho B., Scandling J.D., Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am. J. Transplant. 2008, 8(1):222-227.
71. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Chapman J.R., Allen R.D. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004, 78(4):557-565.
72. Larson T.S., Dean P.G., Stegall M.D., et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am. J. Transplant. 2006, 6(3):514-522.
73. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 2007, 357(25):2562-2575.
74. Vincenti F., Schena F.P., Paraskevas S., Hauser I.A., Walker R.G., Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am. J. Transplant. 2008, 8(2):307-316.
75. Woodle E.S., First M.R., Pirsch J., Shihab F., Gaber A.O., Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann. Surg. 2008, 248(4):564-577.
76. Laftavi M.R., Stephan R., Stefanick B., et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005, 137(3):364-371.
77. Sayegh M.H., Turka L.A. T-cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J. Am. Soc. Nephrol. 1995, 6(4):1143-1150.
78. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 2005, 353(8):770-781.
79. Bluestone J.A., Liu W., Yabu J.M., et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T-cells in renal transplantation. Am. J. Transplant. 2008, 8(10):2086-2096.
80. Vincenti F., Grinyo J.M., Charpentier B., et al. Primary outcomes from a randomized, phase III study of belatacept vs. cyclosporine in kidney transplant recipients (BENEFIT study). Am. J. Transplant. 2009, 9(Suppl. 2):191-192.
81. Durrbach A., Larsen C., Medina-Pestana J.D., et al. Primary outcomes from a randomized, phase III study of belatacept vs. cyclosporine in ECD kidney transplants (BENEFIT-EXT study). Am. J. Transplant. 2009, 9(Suppl. 2):199.
82. Pribila J.T., Quale A.C., Mueller K.L., Shimizu Y. Integrins and T-cell-mediated immunity. Annu. Rev. Immunol. 2004, 22:157-180.
83. Van Seventer G.A., Shimizu Y., Horgan K.J., Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T-cell receptor-mediated activation of resting T-cells. J. Immunol. 1990, 144(12):4579-4586.
84. Moy V.T., Brian A.A. Signaling by lymphocyte function-associated antigen 1 (LFA-1) in B cells: enhanced antigen presentation after stimulation through LFA-1. J. Exp. Med. 1992, 175(1):1-7.
85. Vincenti F., Mendez R., Pescovitz M., et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am. J. Transplant. 2007, 7(7):1770-1777.
86. Chamian F., Lin S.L., Lee E., et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T-cells (Tem) and relative preservation of central memory T-cells (Tcm) in psoriasis. J. Transl. Med. 2007, 5:27.
87. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 2006, 355(12):1233-1243.
88. Locke J.E., Magro C.M., Singer A.L., et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am. J. Transplant. 2008, 9(1):31.